Wall Street closes lower on vaccine delay, dampened stimulus hopes

While all three major stock indexes closed in the red, a gain Microsoft Corp shares helped the mitigate the tech-heavy Nasdaq's loss

coronavirus, wall street, markets
Johnson & Johnson announced on Monday it was pausing clinical trials of a Covid-19 vaccine candidate due to an unexplained illness in a study participant
Reuters
4 min read Last Updated : Oct 14 2020 | 2:12 AM IST
Wall Street lost ground on Tuesday, with halted Covid-19 vaccine trials and an elusive US stimulus agreement weighing on sentiment as third quarter earnings season got underway.

While all three major stock indexes closed in the red, a gain Microsoft Corp shares helped the mitigate the tech-heavy Nasdaq's loss.

Johnson & Johnson announced on Monday it was pausing clinical trials of a Covid-19 vaccine candidate due to an unexplained illness in a study participant. The delay weighed on the company's shares, even after its beat-and-raise earnings report. Its shares lost 2.3 per cent.

Late in the session, rival Eli Lilly & Co said it was also halting its coronavirus antibody trial because of safety concerns, sending its shares down 2.9 per cent.

"We have this recent spike in coronavirus cases coinciding with big drug companies halting vaccine trials," said Robert Pavlik, chief investment strategist at SlateStone Wealth LLC in New York. "That's making the market nervous and in response, you're seeing the lockdown stocks moving higher." Hopes for the passage of a new coronavirus relief package faded as US House Speaker Nancy Pelosi rejected the $1.8 trillion coronavirus relief proposal from the White House, saying it "falls significantly short of what this pandemic and deep recession demand."

Senate Majority Leader Mitch McConnell said the Republican-led Senate would vote on a targeted pared-down stimulus package on Monday."(Washington is) playing with the market's emotions and individuals' financial futures," SlateStone Wealth's Pavlik added. "As this continues, the market is looking past what they're saying because it truly believes stimulus will come some time after the election."

Although JPMorgan handily beat consensus profit estimates, gaining from a boom in its trading business, its peer Citigroup, while also beating expectations, was slammed by low interest rates and a slowdown in loan demand. Their shares dropped 1.6 per cent and 4.8 per cent, respectively.

The broader S&P Banking index lost 2.7 per centApple Inc unveiled the latest incarnation of its flagship gadget, the iPhone 12 with 5G connectivity. Its shares were down 2.7 per cent.The Dow Jones Industrial Average fell 157.71 points, or 0.55 per cent, to 28,679.81, the S&P 500 lost 22.29 points, or 0.63 per cent, to 3,511.93 and the Nasdaq Composite dropped 12.36 points, or 0.1 per cent, to 11,863.90.Third-quarter reporting season has left the starting gate, and analysts now see S&P 500 earnings, in aggregate, falling by 19.6 per cent year-on-year, according to Refinitiv.

Other earnings on tap this week include Bank of America Corp , Goldman Sachs Group Inc, Wells Fargo & Co , UnitedHealth Group and United Airlines Holdings Inc expected on Wednesday, with Morgan Stanley and Honeywell International Inc due on Thursday.

Shares of Delta Air Lines Inc dropped 2.7 per cent after the commercial carrier reported a 76 per cent plunge in quarterly revenue and announced it has delayed a targeted halt to its cash bleed.

Plane maker Boeing Co reported order cancellations for its grounded 737 MAX aircraft and said deliveries were less than half the number as the same month a year ago. Its stock, was down 3.1 per cent was the heaviest drag on the Dow.

Declining issues outnumbered advancing ones on the NYSE by a 2.00-to-1 ratio; on Nasdaq, a 1.50-to-1 ratio favored decliners.

The S&P 500 posted 39 new 52-week highs and one new low; the Nasdaq Composite recorded 123 new highs and 14 new lows.

Volume on US exchanges was 8.50 billion shares, compared with the 9.72 billion average over the last 20 trading days.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Wall StreetUS stocksCoronavirus Vaccine

Next Story